Seeking Your Input on the Next National HIV/AIDS Strategy and National Strategic Plans for STIs, Vaccines, and Viral Hepatitis

This content originally appeared on HIV.Gov. View the full article here.

Summary: The HHS Office of Infectious Disease and HIV/AIDS Policy has issued a Request for Information to gather recommendations that will inform the development of the 2026-2030 National Strategic Plans for STIs, Viral Hepatitis, and Vaccines as well as the 2026-2030 National HIV/AIDS Strategy. Share your feedback online by December 6, 2024.

The HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) is in the process of developing the 2026–2030 national strategic plans for sexually transmitted infections, vaccines, and viral hepatitis. Our office is also collaborating with White House Office of National AIDS Policy (ONAP) to develop the 2026–2030 National HIV/AIDS Strategy.

For the plans to be most relevant and effective, OIDP and ONAP are inviting input from a wide variety of individuals and organizations with an interest in addressing these critical public health issues. As was the case with the current versions of the three national strategic plans and with the current and all the prior editions of the National HIV/AIDS Strategy, gathering input from community members, public health partners, and others is a key first step in the development process.

You can submit your ideas via the online form until December 6, 2024, at 5:00 PM (ET). More details about the opportunity to provide input on any or all of these plans can be found in the Federal Register Notice that formally requests public input.

You can review the NHAS and current National Strategic Plans at these links:

In addition to this Request for Information, OIDP will be hosting three virtual listening sessions in the coming weeks as another means of gathering input. Follow HIV.gov for additional information once the details are finalized.


2024 National Gay Men’s HIV/AIDS Awareness Day

September 27, 2024 – Today, CHIPTS joins partners across the country in observing National Gay Men’s HIV/AIDS Awareness Day, a day when we reaffirm our commitment to ending the disproportionate impact of HIV on gay and bisexual men in the United States. In honor of #NGMHAAD, we are excited to share recent research on this important topic from our CHIPTS faculty. Learn more below.

In 2022, the estimated number of new HIV infections showed a 10% overall decrease among gay and bisexual men compared to 2018, this percentage is significantly lower when observing age-specific data. There is a 31% reduction of new HIV infections among young gay and bisexual men aged 13-24. A similar reduction is captured among Black/African American gay and bisexual men (16% decrease) and White gay and bisexual men (20% decrease). In contrast, the number of new HIV infections among Hispanic/Latino gay and bisexual men remained stable, underscoring the need for better insights and enhanced support for this community.

It is crucial to address inequities as we work to lower infection rates and improve access to treatment. There is a pressing need for more tailored access to HIV testing and prevention services, including ART, PrEP, and PEP. We must also focus on eliminating HIV stigma and other barriers to providing compassionate, culturally competent care.

Several CHIPTS faculty members have conducted research on the impact of HIV, the HIV care continuum, and HIV syndemics as they relate to gay men. Recent publications reflecting this work include:

 

Qian, Y., Detels, R., Comulada, W. S., Hidalgo, M. A., Lee, S. J., Biello, K. B., Yonko, E. A., Friedman, M. R., Palella, F. J., Plankey, M. W., & Mimiaga, M. J. (2024). Longitudinal Analysis of Overlapping Psychosocial Factors Predicting Incident Hospitalization Among Mixed HIV Serostatus Men who have Sex with Men in the Multicenter AIDS Cohort Study. AIDS and behavior, 28(9), 1–12. https://doi.org/10.1007/s10461-024-04356-5

  • Men who have sex with men (MSM) are at increased risk for certain types of chronic diseases and mental health problems. Despite having extended survival in the highly active antiretroviral therapy (HAART) era, MSM living with HIV contend with aging-related diseases and complications with treatment. Consequent hospitalizations incur high costs, fear, low quality of life, and frailty.

Moran, A., Javanbakht, M., Mimiaga, M., Shoptaw, S., & Gorbach, P. M. (2024). Association of Partnership-Level Methamphetamine Use on Inconsistent PrEP Care Engagement Among GBMSM in Los Angeles County. AIDS and behavior, 28(5), 1522–1530. https://doi.org/10.1007/s10461-023-04178-x

  • There are limited quantitative studies describing the association between meth use in the context of male-male sexual partnerships and PrEP care engagement. We assessed the longitudinal relationship between individual and partnership level meth use with inconsistent PrEP engagement among young gay, bisexual and other men who have sex with men (GBMSM) in Los Angeles.

Javanbakht, M., Miller, A. P., Moran, A., Ragsdale, A., Bolan, R., Shoptaw, S., & Gorbach, P. M. (2023). Changes in Substance Use and Sexual Behaviors After a Sexually Transmitted Infection Diagnosis Among a Cohort of Men Who Have Sex With Men in Los Angeles, CA. Sexually transmitted diseases, 50(2), 112–120. https://doi.org/10.1097/OLQ.0000000000001733

  • Despite declines in substance use and sexual behaviors after a sexually transmitted infection, reinfections were high suggesting that men who have sex with men with sexually transmitted infections occupy sexual networks with high transmission probabilities and prevention efforts should consider sexual network characteristics.

Recent Research News Roundup: HIV and Other Infectious Diseases

Summary: NIH’s National Institute of Allergy and Infectious Diseases has recently shared news about mpox research, HIV risk among cisgender women, COVID in people with advanced HIV, syphilis screening and diagnostics, and the future of NIAID’s HIV clinical research enterprise.

 

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has recently shared news about a number of developments of interest to HIV.gov followers. Read this roundup.

NIH Releases Mpox Research Agenda

As part of the U.S. government’s response to the current mpox outbreak, NIAID released an update on its priorities for mpox research.

Study Links Certain Vaginal Bacteria and Inflammatory Marker to Increased Odds of Acquiring HIV Among Cisgender Women

Fourteen vaginal bacterial species and the presence of a protein that promotes inflammation were associated with increased odds of HIV acquisition in a study of more than 500 cisgender women in African countries with high HIV incidence. The study was the largest to date to prospectively analyze the relationship between both the vaginal microbiome and vaginal tissue inflammation and the likelihood of acquiring HIV among cisgender women in this population. Read NIAID’s news release.

SARS-CoV-2 Rapidly Evolves in People with Advanced HIV

A NIAID study revealed how some variants of SARS-CoV-2—the virus that causes COVID-19—could evolve. The researchers used cutting-edge technology to examine genes from SARS-CoV-2 in people with and without HIV who also had COVID-19, looking at the different copies of the virus in individuals over time. They found that people with advanced HIV—as defined by reduced numbers of immune cells called CD4+ T cells—had dozens of SARS-CoV-2 variants in their bodies, compared to just one major variant in most people without HIV and people with HIV who had higher numbers of CD4+ T cells. Read NIAID’s news release about the study.

Emergency Department Screening More Than Doubles Detection of Syphilis Cases

Providing optional syphilis tests to most people seeking care at a large emergency department led to a dramatic increase in syphilis screening and diagnosis, according to an NIH-supported study of nearly 300,000 emergency department encounters in Chicago. Most people diagnosed had no symptoms, which suggests that symptom-based testing strategies alone could miss opportunities to diagnose and treat people with syphilis. The results were published today in the journal Open Forum Infectious DiseasesRead about the NIH-supported study that shows the strategy’s potential to reach people with and without symptoms.

Watch HIV.gov’s interview with Dr. Kimberly Stanford, the study’s author, from this year’s Conference on Retroviruses and Opportunistic Infections.

NIH Awards Will Support Innovation in Syphilis Diagnostics

NIAID has awarded grants for 10 projects to improve diagnostic tools for congenital and adult syphilis—conditions currently diagnosed with a sequence of tests, each with limited precision. The Centers for Disease Control and Prevention estimates that adult and congenital syphilis cases increased by 80% and 183%, respectively, between 2018 and 2022—a crisis that prompted the U.S. Department of Health and Human Services (HHS) to establish a national taskforce to respond to the epidemic. Read the announcement.

Bringing HIV Study Protocols to Life with Representative, High-Quality Research

The HIV clinical trials network sites have made tremendous contributions to NIH’s scientific priorities by offering direct access to and consultation with populations most affected by HIV globally, and by delivering high-quality clinical research with strong connections to trusted community outreach platforms. Future networks will need to maintain core strengths of current models while expanding capacity in areas vital to further scientific progress. These include operations that inform pandemic responses and extending our reach within communities impacted by HIV, including populations historically underrepresented in clinical research. Read more about the future of NIAID’s HIV clinical research enterprise.


NIH Calls for Implementation Science to Help End HIV in the United States

This content originally appeared on NIAID Funding News. View the full article here.

NIAID, along with several other NIH institutes and centers (ICs), has issued a Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE), which solicits implementation science projects to advance the goals of the Ending the HIV Epidemic in the U.S. (EHE) Initiative. The Initiative, launched in 2019, is a bold plan developed by agencies across HHS to substantially reduce new HIV infections in communities disproportionately impacted by HIV.

Awarded projects responsive to this NOSI will have the opportunity to become part of a national network of HIV implementation science researchers, with access to resources and support from the NIH-funded Coordination, Consultation and Data Management Center (CCDMC) and Regional Implementation Science Hubs. Awardees will maximize the public health impact of their projects by working with the CCDMC to report and disseminate study progress and outcomes. In addition to networking with other researchers, awardees will also have opportunities to engage with federal staff across HHS as they contribute to this important national initiative.

Applications to this NOSI must be grounded in implementation science, and address one or more of the four strategies outlined in the EHE initiative:

  • Diagnose all people with HIV as early as possible.
  • Treat people with HIV rapidly and effectively to reach sustained viral suppression.
  • Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs.
  • Respond quickly to potential HIV outbreaks to get needed prevention and treatment services to people who need them.

Applications must also focus on one or more of the 57 EHE geographic priority areas. Projects should support local EHE efforts through meaningful engagement with implementing partners such as public health departments, healthcare organizations, and other service providers, as well as community members and people with lived experience. Interested applicants should refer to the full NOSI for a complete list of requirements.

Examples of programmatic areas of interest include (but are not limited to):

  • Developing and testing strategies to expand engagement and re-engagement in HIV prevention, testing, treatment, care, and response services with a focus on populations that are either disproportionately impacted by HIV or are largely unreached by current programs, or both. This would include populations experiencing unstable housing or homelessness, or people who are currently or formerly incarcerated.
  • Utilizing a syndemics approach to develop and test holistic, multicomponent interventions to sustainably address structural and other social barriers to care and retention such as mental health conditions, substance use, medication adherence, management of chronic health conditions and comorbidities, housing instability, food insecurity, racism, poverty, transportation, and stigma.
  • Designing and testing integrated disease care models to address barriers to HIV prevention or treatment outcomes posed by chronic health comorbidities, including those associated with HIV and aging, and co-infections, including detection, prevention, and treatment of sexually transmitted infections.
  • Developing and testing rapid implementation strategies to improve HIV testing, care, and prevention services among people in sexual and needle-sharing networks affected by rapid HIV transmission such as clusters and outbreaks.
  • Developing effective dissemination approaches for communicating and integrating implementation knowledge to specific audiences, with the goal of scaling-up, replicating, and/or sustaining evidence-based strategies to improve HIV prevention, treatment, and response.

Refer to the full NOSI for additional areas of interest.

Research areas not supported by this NOSI include:

  • Research focused only on surveillance to identify people with HIV who are suboptimally engaged in existing HIV treatment programs.
  • Interventions that are not substantially different from conventional service delivery that failed to engage patients with extensive adherence challenges.
  • Drug or device safety trials with registration requirements.
  • Studies that do not include a multidisciplinary team approach, including a community partner.
  • Projects to develop de novo health interventions with a primary aim of testing efficacy.
  • Research focused on identifying social determinants as risk factors, without implementing interventions.

Application and Submission Information 

This notice applies to due dates on or after September 7, 2024, and subsequent receipt dates through January 9, 2026. Select the IC and associated notice of funding opportunity (NOFO) to use for submission of an application in response to the NOSI (refer to the table below). For funding consideration, include “NOT-AI-24-059” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form.

Note that application details such as budget and project period limitations are set by the specific NOFO through which applicants choose to apply.

Activity Code  NOFO  Title  First Available Due Date  Participating IC(s) 
R01 PA-20-185 NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed) September 7, 2024 NIAID, NHLBI, NIA, NIAAA, NICHD, NIDA, NIMH, NIMHD, NINR
R01 PA-20-183 Research Project Grant (Parent R01, Clinical Trial Required) September 7, 2024 NIAID, NHLBI, NIA, NIAAA, NICHD, NIDA, NIMH, NIMHD, NINR
R21 PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed) September 7, 2024 NIAID, NIA, NIAAA, NICHD, NIDA, NINR
R21 PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Required) September 7, 2024 NIAID, NIA, NIAAA, NICHD, NIDA, NIMH, NINR
R01 PAR-22-105 Dissemination and Implementation Research in Health (R01, Clinical Trial Optional) September 7, 2024 NIAID, NHLBI, NIA, NIAAA, NICHD, NIDA, NIMH, NIMHD, NINR
R21 PAR-22-109 Dissemination and Implementation Research in Health (R21, Clinical Trial Optional) September 7, 2024 NIAID, NIA, NIAAA, NICHD, NIDA, NIMH, NINR
R34 PAR-23-060 Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34, Clinical Trial Optional) September 10, 2024 NIMH
R21 PAR-23-061 Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21, Clinical Trial Optional) September 10, 2024 NIMH
R01 PAR-23-062 Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01, Clinical Trial Optional) September 10, 2024 NIMH
R34 PAS-23-172 HIV Prevention and Alcohol (R34, Clinical Trial Optional) September 7, 2024 NIAAA
R01 PAS-23-173 HIV Prevention and Alcohol (R01, Clinical Trial Optional) September 7, 2024 NIAAA

CHIPTS Director Steve Shoptaw Awarded the UCLA Public Impact Research Award

CHIPTS Center Director Steve Shoptaw, PhD, was recently awarded a UCLA 2024 Public Impact Research Award alongside five other outstanding awardees. Bestowed by the UCLA Office of Research and Creative Activities, this award celebrates the efforts of current faculty translating research into positive public action that benefits local, national, and global communities. Dr. Shoptaw’s award recognizes his longstanding efforts to support people impacted by stimulant use and HIV.

Dr. Shoptaw is a licensed psychologist, Professor in Family Medicine and Psychiatry and Biobehavioral Sciences, and Vice Chair for Research in Family Medicine at UCLA. In addition to his leadership of CHIPTS, he is Director of the UCLA Center for Behavioral and Addiction Medicine (CBAM) and of the UCLA Vine Street Clinic. He is a world-renowned expert on addiction treatment who brings his cutting-edge research straight to those who need it most at the UCLA Vine Street Clinic in Hollywood. His mission at Vine Street is to leverage scientific resources to address high rates of methamphetamine use, HIV infections, and overdose deaths among underserved individuals living in the surrounding area and across Los Angeles.

Dr. Shoptaw’s commitment to Angelenos is further exemplified by his nearly two decades of service as volunteer executive director for Safe House, a facility that provided permanent and emergency housing for those living with HIV/AIDS, substance use, and mental health disorders from 1996 to 2013. He now uses a mobile clinic to bring integrated health care services focused on addiction medicine and infectious diseases to those who are unstably housed, face transportation issues, and encounter other barriers to accessing care.

Dr. Shoptaw’s “Case-based Learning Collaborative on Stimulants” series stands out as another notable achievement. The Collaborative is a nationally recognized forum led by his addiction medicine fellows that educates doctors, nurses, social workers, and community stakeholders on best practices in implementing evidence-based addiction medicine approaches.

One of his most transformative research contributions has been his foundational work with contingency management for those who use cocaine or methamphetamine. Dr. Shoptaw advises Los Angeles County stakeholders, clinicians, and community-based organizations on how to implement this therapy — which positively reinforces desired behaviors – to help people reach their substance use-related goals.

Learn more about the Awards and other 2024 awardees on the Public Impact Research (PIR) Awards webpage.

CDC Announces Availability of $7 Million to Accelerate PrEP Uptake in EHE Jurisdictions

This content originally appeared on HIV.Gov. View the full article here.

Summary: New CDC funding will support efforts in EHE jurisdictions to increase PrEP access and uptake among priority populations disproportionately affected by HIV and low PrEP prescriptions.

The Centers for Disease Control and Prevention (CDC) recently issued a new competitive supplemental funding opportunity to increase PrEP access and uptake among priority populations and eliminate structural and social barriers that prevent equitable access to PrEP within EHE jurisdictions. The new funding opportunity is open to the health departments currently receiving funding for the Ending the HIV Epidemic in the U.S. (EHE) initiative through PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments. This supplemental program aims to accelerate progress toward meeting the National HIV/AIDS Strategy (2022-2025) and EHE goal of 50% PrEP coverage by the end of 2025.

CDC expects to award approximately $7 million to up to four health departments to support efforts to accelerate PrEP uptake focused on priority populations disproportionately affected by HIV and low PrEP prescriptions (i.e., Black and Latino gay, bisexual, and other men who have sex with men, and Black cisgender and transgender women) through patient navigation/case management services and improved access to and utilization of existing PrEP services not covered by other financial resources.

In addition to increasing PrEP access and uptake, these programs will incorporate elements to increase HIV non-occupational post-exposure prophylaxis (PEP) and STI doxycycline post-exposure prophylaxis (doxy PEP) awareness and access, including activities with clinicians, non-clinical community-based organizations, and persons at risk for HIV acquisition.

Applications are due by August 31, 2024.

White House Seeking Community Input on 2026-2030 National HIV/AIDS Strategy

This content originally appeared on HIV.Gov. View the full article here.

Summary: The White House and HHS are seeking public input on the development of the next National HIV/AIDS Strategy and national strategic plans for STIs, viral hepatitis, and vaccines. Participants at the National Ryan White Conference are encouraged to share their ideas on August 20. Other opportunities for input to follow.

The White House Office of National AIDS Policy (ONAP) and HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) have initiated the process to develop the next National HIV/AIDS Strategy (NHAS), which will cover 2026-2030. Concurrently, OIDP will be developing the next iterations of the STI National Strategic Plan, Viral Hepatitis National Strategic Plan, and Vaccines National Strategic Plan. The current NHAS spans 2022-2025 and the three national strategic plans also continue through 2025.

While federal, state, and community partners continue to implement those plans, ONAP and OIDP are beginning the processes to thoughtfully develop the next iterations of these plans by gathering public input. The first of several opportunities for community members to share their ideas will be on Tuesday, August 20, 2024, at the National Ryan White Conference in Washington, DC. A listening session will be held from 9:00 AM to 10:00 AM at the conference hotel. Conference participants are encouraged to join this session and share their ideas, recommendations, and feedback.

Additional listening sessions are planned, including at the upcoming U.S. Conference on HIV/AIDS in New Orleans. Written suggestions will also be sought through a Request for Information that will be published in the Federal Register soon.

Members of the California Statewide HIV and Aging Educational Initiative team at the Statewide Skill-BuIlding Symposium

Statewide Skill-Building Symposium: Addressing Mental Health among Older Adults with HIV Recap

In honor of HIV Long-Term Survivors Awareness Day, the California Statewide HIV and Aging Educational Initiative in partnership with Santa Clara County Getting to Zero hosted the Statewide Skill-Building Symposium: Addressing Mental Health among Older Adults with HIV on Wednesday, June 5, 2024, from 8:30 AM-4:30 PM PT at the Orchard City Banquet Hall in Campbell, CA. This one-day, in-person symposium aimed to help equip California service providers and frontline staff to better address the mental health needs of older adults with HIV, including the unique needs of long-term survivors.

During the symposium, leading experts offered engaging, interactive presentations on the intersection of mental health and loneliness & isolation, physical & cognitive decline, substance use, and other key issues impacting older adults with HIV. View the agenda with recorded presentations linked for each presentation below. You can also view the complete set of recorded presentations in our Statewide Skill-Building Symposium YouTube Playlist.

8:30-9:00 AM Check-In and Continental Breakfast
9:00-9:15 AM Welcome and Opening Remarks

California Statewide HIV and Aging Educational Initiative and Santa Clara County Getting to Zero

9:15-9:25 AM Update from the Office of AIDS: HIV, Aging, and Mental Health

Philip Peters, MD, Medical Officer, Office of AIDS, California Department of Public Health

9:25-10:10 Keynote Address — Four A’s of Caring for Our Elder HIV Community: Ask, Acknowledge, Advocate, and Amplify

William Hua, PhD, Clinical Psychologist and Executive Director, Alliance Health Project, UCSF

10:10-10:20 AM Break
10:20-11:50 AM Take Action on Loneliness and Isolation

11:50 AM-12:50 PM Lunch
12:50-2:20 PM Take Action on Physical and Cognitive Decline

2:20-2:30 PM Break
2:30-4:00 PM Take Action on Taboo Topics: Sexual Health and Substance Use

4:00-4:20 PM Local Reflections and Call to Action

Harsha Ramchandani, MD, Chief Medical Officer, Bay Area Community Health (BACH)

4:20-4:30 PM Closing Remarks
California Statewide HIV and Aging Educational Initiative

The California Statewide HIV and Aging Educational Initiative is a collaborative capacity-building initiative led by CHIPTS, APLA Health, the Pacific AIDS Education and Training Center (PAETC)—LA and BANCC, and the San Francisco AIDS Foundation. If you have any questions, please contact Elena Rosenberg-Carlson at erosenberg-carlson@mednet.ucla.edu.

Zero HIV Stigma Day Redefines Narratives

This content originally appeared on HIV.Gov. View the full article here.

Summary: HIV.gov highlights why Zero HIV Stigma Day is relevant in 2024 and how this awareness day addresses stigma.

July 21st is the second annual Zero HIV Stigma Day, which helps raise awareness about HIV stigma and how to help stop it. This year’s theme, “Beyond Labels: Redefining HIV Narratives,” is a call to move beyond stereotypes associated with people with HIV and to celebrate the decades of advocacy that is changing those narratives. The day coincides with the birthday of Prudence Mabele, an activist who was the first woman in South Africa to disclose her HIV status in 1992.

Zero HIV Stigma Day is a joint initiative of NAZ and the International Association of Providers of AIDS Care (IAPAC)Exit Disclaimer in collaboration with the Global HIV Collaborative and Fast-Track Cities Institute. To highlight why this awareness day matters in 2024, HIV.gov spoke with Kalvin Pugh, Senior Advisor, Community Engagement, IAPAC.

Mr. Pugh said stigma doesn’t just impact those with HIV, but it also prevents individuals from accessing services for testing or prevention. He added that the global awareness day is making an impact on reducing stigma.

“Since this is the second commemoration, the noticeable differences that I saw were on a community level and on a personal level with folks who I interacted with last year, those who felt that the Human First film was really touching for them and elevated the different aspects of stigma that people interact with daily.”

Mr. Pugh said one of the most notable outcomes of the awareness day is that a young woman in the UK who has had HIV for a long time finally felt comfortable enough to disclose her status on social media and share that she was doing just fine.

“I think the further we go, the more we elevate these messages, the better, and the more outcomes we hope to improve,” he said, adding that stigma may never be eliminated, but we can all do our part. “What we really need to do if we’re going to save the planet and move humanity forward is show kindness and compassion.”

HIV-related stigma is addressed in the National HIV/AIDS Strategy, which calls on all sectors of society to work together to combat stigma and discrimination to reduce new transmissions and improve health outcomes for people with HIV.

CHIPTS at AIDS 2024

The 25th International AIDS Conference (AIDS 2024), will take place in Munich, Germany, from July 22-26, 2024. Pre-conferences will be held on July 20-22, 2024. Learn more about AIDS 2024 and the exciting work of our CHIPTS scientists featured at the conference below.

What is AIDS 2024?

The International AIDS Conference is the world’s largest conference on HIV and AIDS. As a global platform to advance the HIV response, it sits uniquely at the intersection of science, advocacy, and human rights. The 25th International AIDS Conference, AIDS 2024, will convene thousands of people living with, affected by, and working on HIV to share knowledge, best practices, and lessons learned from the HIV response over the past 40 years.

The theme for AIDS 2024, “Put people first,” reflects the organizers’ acknowledgment of the HIV pandemic as a significant threat to public health and individual well-being. This principle of prioritizing people is essential in guiding efforts aimed at ending the HIV pandemic.

CHIPTS at AIDS 2024

Several CHIPTS scientists will be sharing exciting research findings and project updates at AIDS 2024, contributing to the dissemination of crucial information that advances HIV prevention and treatment initiatives globally. We are delighted to highlight satellite sessions, oral session abstracts, and poster session abstracts featuring the important work of our CHIPTS scientists.

Monday, July 22, 2024

Satellite Session

SAT015 – HIV-related intersectional stigma reduction and discrimination intervention findings from NIH Promoting Reductions in Intersectional StigMa (PRISM) clinical trials

  • Session Start: 9:30 AM (Room 5/Channel 8)
  • Presentation Title: A CBT-group intervention to increase HIV testing and PrEP use among Latino sexual minority men (R01MH121256; NCT04225832) (Laura Bogart)
Tuesday, July 23, 2024

Oral Abstract Session

OAE04 – Advanced HIV disease: Hiding in plain sight

  • Session Start: 3:00 PM (Room 14b/Channel 3)
  • Presentation Title: Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study (Raphael Landovitz)

Poster Session

Poster Abstract – TUPEC186

  • Session Start: 12:00 PM
  • Poster Title: Technology-based Interventions, with a stepped care approach, for reducing sexual risk behaviors and increasing PrEP initiation among Transgender and Gender Expansive Youth and Young Adults (ATN 160)
  • Authors: K.J. Horvath, D. Cain, J.A. Rusow, D. Benkeser, L. Schader, B.A. Gwiazdowski, S.J. Skeen, M. Hannah, M. Belzer, M. Castillo, K.H. Mayer, M.E. Paul, J. Hill-Rorie, N. Dorcey-Johnson, J. McAvoy-Banerjea, T. Sanchez, P.S. Sullivan, L. Hightow-Weidman, C.J. Reback
Wednesday, July 24, 2024

Satellite Session

SAT074 – Latching onto freedom: A global dialogue on reproductive justice for women living with HIV

  • Session Start: 7:00 AM (Room 14a/Channel 9)
  • Presentation Title: Dignified breastfeeding for women living with HIV through the U=U framework (Dvora Davey)

Poster Sessions

Poster Abstract – WEPEB101

  • Session Start: 12:00 PM
  • Poster Title: Prediction of intracellular tenofovir-diphosphate concentrations during pregnancy using a semi-mechanism-based population pharmacokinetic model
  • Authors: Yu, R. Bies, J. Momper, B. Best, M. Mirochnick, R. Heffron, C. Celum, K. Brooks, P. Anderson, M. Marzinke, D. Joseph Davey, L. Myer, G. Doncel, C. Hendrix, R. Scott

Poster Abstract – WEPEC206

  • Session Start: 12:00 PM
  • Poster Title: “Everyone should have access to it”: perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial
  • Authors: Psaros, R.J. Landovitz, E.M. Waldron, W. Rice, C.F. Kelley, T. Oyedele, L. Coehlo, N. Phanuphak, Y. Singh, K. Middelkoop, S. Griffith, M. McCauley, A.M. Rivas, O.Y. Chen, T. Jupimai, N. Lawrence, G. Goodman, J. Rooney, A. Rinehart, J. Clark, V. Go, J. Sugarman, S. Fields, A. Adeyeye, B. Grinsztejn, S.A. Safren

Poster Abstract – WEPEE545

  • Session Start: 12:00 PM
  • Poster Title: Telemedicine to improve health equity in two federally qualified health centers in Los Angeles: is telephone the answer?
  • Authors: Walker, C. Moucheraud, D. Butler, J. de Vente, K. Tangonan, C. Takayama, T. Horn, S. Shoptaw, J.S. Currier, J. Gladstein, R. Hoffman

Poster Abstract – WEPEC307

  • Session Start: 12:00 PM
  • Poster Title: Effect of high-risk mobility on treatment interruption among men in Malawi: secondary analysis of two randomized controlled trials
  • Authors: Thorp, K. Balakasi, M. Ramesh, I. Robson, A. Choko, R. Hoffman, S. Shoptaw, K. Dovel

Poster Abstract – WEPEC302

  • Session Start: 12:00 PM
  • Poster Title: Acceptability of long-acting injectable antiretroviral treatment (LAI-ART) among young Black sexual minority men (SMM) living with HIV in the Southern United States
  • Authors: Ogunbajo, W. Vincent, D. Siconolfi, C. Campbell, L. Pollack, S. Kegeles, G. Rebchook, S. Tebbetts, E. Storholm

Poster Abstract – WEPED343

  • Session Start: 12:00 PM
  • Poster Title: Implementation of a hybrid online-offline intervention to address HIV stigma and gender disparity for women living with HIV in Vietnam
  • Authors: C. Lin, B.D. Nguyen, H. Dang, T.T. Nguyen, L. Li, M.G. Le
Thursday, July 25, 2024

Poster Sessions

Poster Abstract – THPEE516

  • Session Start: 12:00 PM
  • Poster Title: FastPrEP: evaluating factors associated with PrEP initiation from community-based mobile clinics compared to fixed-site primary health facilities in adolescents and young people in Cape Town, South Africa
  • Authors: Rousseau, K. Lebelo, N. Mathola, P. Macdonald, O. Vanto, P. Fuzile, P. Smith, T. Wonxie, L. Fynn, M. Wallace, D. Davey, L.-G. Bekker

Poster Abstract – THPEC176

  • Session Start: 12:00 PM
  • Poster Title: Impact of changing PrEP regimens on retention among men who have sex with men in Hanoi, Vietnam (2020-2023)
  • Authors: Q.L. Pham, N. Setrakian, H.T. Bui, P. Adamson, T.N. Hoang, L.M. Giang, P.M. Gorbach

Poster Abstract – THPEA029

  • Session Start: 12:00 PM
  • Poster Title: A first-in-human phase 1 trial of PGT121.414.LS administered alone and in combination with VRC07-523LS: safety, tolerability, pharmacokinetics, and neutralization activity (HVTN 136/HPTN 092)
  • Authors: Edupuganti, C. Hurt, K. Stephenson, Y. Huang, C. Paez, C. Yu, C. Yen, B. Hanscom, Z. He, M. Miner, T. Gamble, J. Heptinstall, K.E. Seaton, A. Eaton, S. Regenold, W. Chege, M. Anderson, N. McCloskey, L. Zhang, E. Piwowar-Manning, M.E. Ackerman, M. Pensiero, B. Dye, R.J. Landovitz, K.H. Mayer, M. Siegel, M. Sobieszczyk, S.R. Walsh, L. Gama, D.H. Barouch, D. Montefiori, G. Tomaras, HVTN136/HPTN 092 study team

Poster Abstract – THPEC292

  • Session Start: 12:00 PM
  • Poster Title: Increasing COVID-19 vaccine coverage among art clients through a comprehensive vaccination intervention in Kasungu district, Malawi
  • Authors: Chivwara, C. Saini, R. Khunga, E. Makwakwa, H. Kanise, J. Njala, D. Smith, S. Phiri, C. Moucheraud, E. Chikuse, R. Hoffman, J. van Oosterhout

Poster Abstract – THPED380

  • Session Start: 12:00 PM
  • Poster Title: HPTN 094: engaging key community stakeholders in preparation for mobile clinics providing integrated health services (medication for opioid use disorder and HIV treatment/prevention services) for people who inject drugs (PWID)
  • Authors: Albano, J. Harris, C. Blades, A. Davis, J. Lucas, S. Alvarado, J. Yeager, S. Edwards, P. Andrew, N. El-Bassel, S. Shoptaw

Poster Abstract – THPED326

  • Session Start: 12:00 PM
  • Poster Title: Health or income? How men living with HIV in Malawi experience and navigate decisions between income generation and ART refills
  • Authors: Ramesh, K. Balakasi, J. Hubbard, M. Thorp, L. Kamtsendero, M. Sanena, S. Phiri, M. Cornell, T. Coates, K. Holland, A. Choko, K. Dovel

Poster Abstract – THPEC277

  • Session Start: 12:00 PM
  • Poster Title: Factors associated with repeat treatment interruption among men in Malawi: findings from two randomized control trials
  • Authors: K.T. Balakasi, M. Thorp, I. Robson, M. Mphande, C. Lemani, A. Choko, S. Phiri, R. Hoffman, T.J. Coates, K. Dovel

Poster Abstract – LB18

  • Session Start: 12:00 PM
  • Poster Title: Efficacy and safety of ensitrelvir in non-hospitalized adults at standard or high risk of progression to severe COVID-19: the SCORPIO-HR phase 3, randomized, double-blind, placebo-controlled trial
  • Authors: K. Chew, A. Luetkemeyer, S. Lacey, M. Hughes, L. Harrison, E. Daar, J. Eron, C. Fletcher, A. Greninger, D. Hessinger, J. Li, D. Mailhot, D. Wohl, M. Chayakulkeeree, P. Elistratova, O. Makinde, G. Morgan, S. Portsmouth, T. Uehara, D. Smith, J. Currier, on behalf of the SCORPIO-HR/ACTIV-2d (ACTG A5407) study team

Poster Abstract – LB32

  • Session Start: 12:00 PM
  • Poster Title: Understand how health, well-being, social support, violence, and stigma shape resilience pathways among Kenyan youth aged 15-24 living with HIV in urban informal settlements through structural equation modeling
  • Authors: Wang, H. Owoko, C. Kabiru, P. Gorbach, S. Muyingo
Friday, July 26, 2024

Oral Abstract Session

OAD37 – Exploring the kaleidoscope of experiences among people living with HIV

  • Session Start: 12:00 PM (Room 5/Channel 8)
  • Presentation Title: Primary outcomes of an intervention employing a hybrid online-offline approach to address HIV stigma among women living with HIV in Vietnam (Chunqing Lin)

Poster Sessions

E-Poster Abstract – EPB026

  • Session Start: 12:00 PM
  • Poster Title: Association of antiretroviral therapy with cognition and resting-state functional connectivity in people with HIV
  • Authors: Ibnidris, J. Ipser, T. M. Nir, L. Chang, R. A. Cohen, T. Ernst, K. J. Kallianpur, E. C. Porges, C. M. Shikuma, S. Thomopoulos, H. J. Zar, P. M. Thompson, S. Shoptaw, D. J. Stein, N. Jahanshad, ENIGMA HIV Working Group

E-Poster Abstract – EPE158

  • Session Start: 12:00 PM
  • Poster Title: Assessing preferences of long-acting PrEP modalities among oral PrEP-experienced postpartum individuals in Cape Town, South Africa: a qualitative study
  • Authors: Wara, L. Court, K. Moopelo, N. Mashele, C. Ntwasa, R. Mvududu, A. Miller, S. Schoetz Dean, C. Orrell, L. Knight, L. Myer, R. Hoffman, D. Joseph Davey

To learn more about AIDS 2024 and access the conference materials, visit: https://www.iasociety.org/conferences/aids2024